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Metformin for diabetes prevention: update of the evidence base
Ulrike Hostaleka and Ian Campbellb
aGlobal Medical Affairs, Merck Healthcare KGaA, Darmstadt, Germany; bUniversity of St Andrews, St Andrews, UK
ABSTRACT
We have conducted a narrative review based on a structured search strategy, focusing on the effects
of metformin on the progression of non-diabetic hyperglycemia to clinical type 2 diabetes mellitus.
The principal trials that demonstrated a significantly lower incidence of diabetes in at-risk populations
randomized to metformin (mostly with impaired glucose tolerance [IGT]) were published mainly from
1999 to 2012. Metformin reduced the 3-year risk of diabetes by 31% in the randomized phase of the
Diabetes Prevention Program (DPP), vs. 58% for intensive lifestyle intervention (ILI). Metformin was
most effective in younger, heavier subjects. Diminishing but still significant reductions in diabetes risk
for subjects originally randomized to these groups were present in the trial’s epidemiological follow-
up, the DPP Outcomes Study (DPPOS) at 10 years (18 and 34%, respectively), 15 years (18 and
27%), and 22 years (18 and 25%). Long-term weight loss was also seen in both groups, with bet-
ter maintenance under metformin. Subgroup analyses from the DPP/DPPOS have shed important light
on the actions of metformin, including a greater effect in women with prior gestational diabetes, and
a reduction in coronary artery calcium in men that might suggest a cardioprotective effect.
Improvements in long-term clinical outcomes with metformin in people with non-diabetic hypergly-
cemia (“prediabetes”) have yet to be demonstrated, but cardiovascular and microvascular benefits
were seen for those in the DPPOS who did not vs. did develop diabetes. Multiple health economic
analyses suggest that either metformin or ILI is cost-effective in a community setting. Long-term dia-
betes prevention with metformin is feasible and is supported in influential guidelines for selected
groups of subjects. Future research will demonstrate whether intervention with metformin in people
with non-diabetic hyperglycemia will improve long-term clinical outcomes.
ARTICLE HISTORY
Received 18 June 2021
Revised 6 July 2021




diabetes mellitus, type 2
Introduction
A new diagnosis of type 2 diabetes mellitus (henceforth referred
to as “type 2 diabetes” for brevity) is life-transforming, requiring
a life-long burden of healthcare, the need to understand and
accept the associated risks of adverse long-term outcomes, and
financial and other consequences1. The management of people
at risk of developing type 2 diabetes, therefore, needs to be con-
ducted with care, to avoid labeling them with the same kind of
issues. Evidence has built in recent years that so-called
“prediabetes” (see below for a discussion of the use of this term)
is associated with an increased long-term risk of death or cardio-
vascular disease, compared with people with normal glucose
regulation, especially in people who already have atherosclerotic
cardiovascular disease (Figure 1)2,3. This has led to an increasing
interest in earlier intervention in the time course of dysglycemia,
focusing on the period before type 2 diabetes is diagnosed.
At the time of writing, metformin has a therapeutic indica-
tion for the prevention or delay of a new diagnosis of type 2
diabetes in at-risk subjects in 66 countries4. Influential guidelines
for the management of dysglycemia or cardiovascular risk now
acknowledge a role for metformin for diabetes prevention in
defined subgroups of people at risk of developing diabetes due
to the presence of prediabetes/non-diabetic hyperglycemia (see
Box 1 for diagnostic criteria for the diagnosis of these
conditions5–7).








<100 (<5.6) <140 (<7.8)
Impaired fasting
glucose (IFG)
100–125 (5.6–6.9)a Non-diabetic: <200 (11.1)
Isolated IFG 100–125 (5.6–6.9) <140 (<7.8)
Impaired glucose
tolerance (IGT)
Non-diabetic: <126 (7.0) 140–199 (7.8–11.0)
Isolated IGT <100 (<5.6) 140–199 (7.8–11.0)
Combined IFG/IGT 100–125 (5.6–6.9) 140–199 (7.8–11.0)
FPG: fasting plasma glucose; IFG: impaired fasting glucose; IGT: impaired
glucose tolerance; NGT: normal glucose tolerance. Adapted from Reference8
under the terms of the Creative Commons Attribution-NonCommercial 4.0
International License (http://creativecommons.org/licenses/by-nc/4.0/).
aThe 100mg/dL/5.6mmol/L cut-off for IFG applies to guidance from
the American Diabetes Association5 and the European Association for
the Study of Diabetes/European Society of Cardiology6; the lower cut-
off for diagnosing IFG is 110mg/dL (6.1mmol/L ) according to the
World Health Organization7.
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We conducted a detailed review of the effects of metformin
for diabetes prevention in 20158. Given the continuing expan-
sion in the therapeutic use of metformin for this purpose, we
have revisited this area. In the current review, we have sum-
marized the current evidence base for diabetes prevention with
metformin, with a focus on new studies and guidelines.
About this review
The main source of literature for this narrative literature
review was from a PubMed search for “metformin [ti] AND
(diabetes [ti] OR prediabetes OR non-diabetic hyperglycemia OR
‘impaired glucose tolerance’ OR IGT OR ‘impaired fasting glu-
cose’ OR IFG OR ‘gestational diabetes’) AND (prevention OR
delay)”. The 732 search hits (14 May 2021) were examined by
eye for articles of interest. The contents of reference lists
of selected studies and references provided by authors
provided additional material for inclusion. The literature on
this subject is large. Accordingly, we have divided our
review into two main parts: concise highlights of material
included in our previous review published in 20158, and a
more detailed account of later evidence published since then.
Prior gestational diabetes mellitus (GDM) and polycystic
ovary syndrome (PCOS) are also important risk factors for
developing clinical (permanent) type 2 diabetes. We have
included a brief review of the literature that explored the
potential of metformin to prevent diabetes onset in subjects
with these conditions. These aspects are dealt with separ-
ately to the main subject of prevention or delay of type 2
diabetes. The effects of metformin on glycemia in established
GDM, on maternal or fetal pregnancy outcomes, or
complications of pregnancy, are beyond the scope of our
review and are not discussed here.
The term, “prediabetes” remains widely used, including by
the American Diabetes Association (ADA) in its Standards of
Care for 20219. This term has attracted controversy, however,
partly due to a perception that large numbers of people
with “prediabetes” will never develop clinical diabetes, but
are nevertheless associated with it, and thus become
“medicalized”10. The World Health Organization has aban-
doned the term in favor of “intermediate hyperglycemia”5.
Nevertheless, much of the relevant literature is based on this
term and we have used it in this review to reflect this where
unavoidable. Where possible, however, we have used the
term, “non-diabetic hyperglycemia”.
Randomized diabetes prevention trials with
metformin in subjects with impaired glucose
tolerance or impaired fasting glucose at baseline
Earlier randomized trials (2015 or earlier)
An overview of earlier evidence relating to diabetes preven-
tion with metformin from randomized trials (including post-
randomization epidemiological follow-up) is presented in
Table 1. Diabetes prevention with metformin was demon-
strated initially in small, randomized, placebo-controlled stud-
ies in China that compared the effects of metformin on
diabetes incidence with placebo (published in 199911 and
200112) in populations with impaired glucose tolerance (IGT).
The large (N¼ 3234) Diabetes Prevention Program (DPP) in
the USA in subjects with IGT and high-normal fasting plasma
glucose (FPG) provided the definitive evidence to support the
concept of diabetes prevention with metformin in 200314.
Other randomized trials also demonstrated a significant
level of diabetes prevention with metformin, including the
Indian DPP (subjects with IGT, metformin vs. standard life-
style advice or intensive lifestyle intervention, published in
2006)33, the CANOE study in Canada (metforminþ low-dose
thiazolidinedione vs. placebo, also published in 2010)34, and
a study in Pakistan (metformin vs. standard lifestyle advice,
published in 2012)35, The Early Diabetes Intervention Trial
found no significant effect of metformin on diabetes inci-
dence in subjects with IFG and/or IGT.
Subgroup analyses from the diabetes
prevention program
Numerous subsidiary publications from the DPP are summar-
ized in Table 1. Metformin improves insulin-stimulated glucose
metabolism in subjects with non-diabetic hyperglycaemia36,37;
this raises the question of whether a short-term pharmacologic
reduction in glucose was masking the presence of type 2 dia-
betes in the metformin group. An analysis from the DPP
showed that the reduction in the risk of incident diabetes with
metformin changed from 31% (at the end of metformin treat-
ment) to 25% (after 1–2 weeks of washout)15. Accordingly,
the majority of the effect of metformin on new type 2 diabetes
Figure 1. Risks of adverse clinical outcomes associated with non-diabetic
hyperglycaemia according to the presence or absence of atherosclerotic cardio-
vascular disease (ASCVD) from a meta-analysis of 129 studies involving a total
of more than 10 million participants. Composites of acardiovascular disease
(CVD) and bcoronary heart disease (CHD) were as reported in individual studies
within this meta-analysis. All forms and definitions of non-diabetic hypergly-
caemia were included, also as reported in individual studies. Drawn from data
presented in reference2.
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incidence did not appear to have been due to metformin’s
antihyperglycemic effect masking an underlying diabetic state.
Another important analysis assessed the effects of 19 clin-
ical variables measured at baseline on the likelihood of pro-
gressing from IGT to diabetes or reverting to normal glucose
tolerance (NGT)17. Predictors of a change in glycemic status
were generally different for the metformin and ILI groups:
 Age, current smoking, prior diagnosis of PCOS, family his-
tory of diabetes, and lower adherence to interventions
predicted progression to diabetes in the metformin
group only;
 Physical activity >150min/week predicted progression to
diabetes in the ILI group only;
 Higher FPG and higher triglycerides predicted progression
to diabetes in both the metformin and ILI groups.
Predictors for regression to NGT were:
 Male gender, a college graduate degree, and lower sys-
tolic blood pressure SBP predicted reversion to NGT on
metformin only;
 Lower FPG, lower triglycerides, and lower age-predicted
reversion to NGT on both ILI and metformin (no baseline
parameter predicted reversion to NGT on ILI only).
The effects of metformin on cardiovascular risk factors
were modest in the DPP, with larger effects seen in the ILI
group18,19. Nevertheless, randomization to metformin was
associated with a significant reduction in the incidence of
the metabolic syndrome during the study (by 17%
[p¼ .03], again with a larger effect of ILI [41% [p< .001])19.
In general, effects on cardiovascular risk factors were driven
Table 1. Diabetes prevention with metformin from randomised trials: highlights up to 2015.
Study Main findings
Li et al.11 66% RRR for metformin vs. placebo in 70 subjects with IGT
Wenying et al.12 RRR for new-onset diabetes vs. standard lifestyle advice were 88% for additional metformin; 87% for
acarbose, 43% for ILI, in 321 subjects with IGT
EDITa,13 No significant effects on the risk of diabetes vs. placebo in subjects with IFG treated with metformin (RRR 0.99,
p¼ .94) or metforminþ acarbose (RRR 1.02, p¼ .91); similar results were seen in those who also had IGT at
baseline (RRR 1.09, p¼ .70 [metformin alone], and RRR 0.72, p¼ .27 [metforminþ acarbose]).
Diabetes Prevention Program (DPP) Main analysis
Relative risk reductions (RRR) of 31% with metformin and 58% with ILI (both vs. placeboþ standard lifestyle
advice) over 3.2 y in a population of 3324 subjects with IGT and high-normal FPG14
NNT to prevent 1 incident case of diabetes was 6.9 (ILI) and 13.9 (metformin)
Median delay in diabetes onset 3 years for metformin and 11 years for ILI
Mean weight loss was 5.6 kg (ILI), 3.1 kg (metformin) and 0.1 kg (placebo)
Metformin was more effective in younger subjects and subjects with higher BMI (similar efficacy for metformin
and ILI for those with BMI 35 kg/m2 or age 44 years)
Later subgroup analyses
About one quarter of the effect of metformin on the risk of new-onset diabetes was due to a short-lived effect
of treatment that reversed on washout15
Metformin (RRR 49 vs. 23%) and ILI (RRR 68 vs. 47%) were more effective (p¼ .03) in preventing
diabetes in subjects who completed college education16
11/19 baseline clinical variables predicted transition to diabetes and 6/19 predicted reversion to NGT17
Larger effect on cardiovascular risk factors (hypertension, dyslipidemia) in the ILI group vs. other groups (driven
largely by changes in glycemic status)18,19
Metformin and ILI reduced the level of atherogenic small, dense LDL20
The incidence vs. placebo of the metabolic syndrome was reduced by 41% on ILI (p< .001) and by 17% on
metformin (p¼ .03)19
Cardiovascular risk factors deteriorated on progression to diabetes and reverse during reversion to NGT (effects
were largest in the ILI group)21
Serum ALT was lower for metformin vs. placebo, mostly mediated by weight loss22
Metformin and ILI reduced C-reactive protein and tPA (and to a lesser extent, fibrinogen) vs. placebo (effects
were larger in the ILI group)23 – but only in those who did not develop diabetes24
Renal function remained similar in each group25,26
Loss of ovarian function in women (post-menopause or oophorectomy) had no effect on diabetes risk.27
Small increases in HRQoL for ILI only (no effect of metformin or placebo), associated with weight loss and
increased physical activity28
Genetic variants associated with a metformin transporter (SLC47A1, SLC22A1) and components of the AMP
kinase system influenced the diabetes prevention response to metformin29
Higher levels of a genetic risk score known to predict lower insulin sensitivity did not alter the improvements in
insulin sensitivity seen with metformin or ILI30
Cost/QALY was USD 1100 for ILI and USD 31,300 for metformin (ILI dominated metformin for incremental cost-
effectiveness;); health system perspective31
Costs per case of diabetes prevented/delayed were USD 13,200 (ILI) and USD 14,300 (metformin) from a societal
perspective32
Indian DPP33 Similar RRR for new-onset diabetes vs. standard lifestyle advice for metforminþ standard lifestyle advice
(26%); metforminþ ILI (28%); ILI (29%) in 531 subjects with IGT
CANOE34 RRR for new-onset diabetes vs. standard lifestyle advice was 77% for additional twice-daily low-dose
metformin (500mg) þ rosiglitazone (2mg) in 207 subjects with IGT
Iqbal Hydrie et al.35 RRR for new-onset diabetes vs. standard lifestyle advice was 77% for additional metformin in 317 subjects
with IGT
ALT: alanine aminotransferase; FPG: fasting plasma glucose; HRQoL: health-related quality of life; ILI: intensive lifestyle intervention.
Figures in parentheses are 95% confidence intervals. References are as shown or included in reference8.
aEarly Diabetes Intervention Trial.
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by (especially adverse) changes in glycemic status and trigly-
cerides in this trial21,38. Both metformin and ILI reduced the
level of atherogenic small, dense LDL and raised LDL, while
metformin increased small HDL20. Differences in effects on
HDL-C according to race have been proposed39.
Improvements in the metformin group occurred for the
non-classical cardiovascular risk factors, alanine aminotrans-
ferase (ALT)22, C-reactive protein (CRP)23,40, and tPA23. The
favorable changes in CRP and tPA in the DPP were seen only
in subjects who did not develop diabetes24. Once again,
changes in these risk factors were mainly associated with
weight loss. Indices of renal function, and their effects on
the risk of diabetes, differed little between groups25,26.
Finally, age interacted with the effects of study treatments,
as described above, but menopausal status in women did
not27. Reduced body weight and increased physical activity
also accounted for an increase in health-related quality of life
(HRQoL) in the ILI group28. A reduced frequency of stress
incontinence due to weight loss provided one striking
example of a mechanism of improved HRQoL in the
ILI group41.
The DPP group conducted a detailed analysis of genetic
variants that affected study outcomes in the DPP29. Reduced
risk of diabetes on metformin, but not in other treatment
groups, was seen in subjects with vs. without the single
nucleotide polymorphisms (SNPs) rs2453583 in the SLC47A1
and rs8065082gene (HRs 0.68 [0.54,0.86] and 0.78 [0.64, 0.96],
respectively), and rs315978 in the LC22A1 gene (HR 0.67
[0.47, 0.96]); both of these genes encode metformin trans-
porters. The presence of rs11086926 in the ABCC8 gene,
which encodes the SUR sulphonylurea receptor (HR 0.79
[0.63, 0.98]) was also associated with a reduced risk of dia-
betes on metformin. Increased progression to diabetes was
associated with SNPs rs11086926 of the HNF4a gene (hepato-
cyte nuclear factor 4a; HR 1.81 [1.35, 2.43]), rs10213440 of
the PPARGC1A gene (a transcriptional coactivator involved in
energy metabolism; HR 1.31 [1.03, 1.66]), rs4424892 of the
MEF2A gene and rs6666307 of the MEF2D gene (both tran-
scriptional regulator involved in the physiological response
to exercise; HRs 1.31 [1.14, 1.80], and 2.15 [1.22,3.80],
respectively).
Elsewhere, adverse genetic risk scores for diabetes also pre-
dicted increased risk of diabetes in the DPP population but did
not interact importantly with the effects of individual study
treatments42–44. A mutation associated previously with an
increased antihyperglycemic response to metformin (the
rs11212617 polymorphism in the ataxia-telangiectasia-mutated
gene giving rise to the C vs. A allele) did not affect the ability
of metformin to prevent or delay diabetes45. A single nucleo-
tide polymorphism known to be associated with obesity
(rs2815752 in the NEGR1 gene) was associated with long-term
weight loss with metformin; 15 other SNPs were not46.
Another study derived a genetic risk score based on 17 muta-
tions known to affect insulin sensitivity: treatment with metfor-
min or ILI improved the insulin sensitivity index irrespective of
the level of this score30.
Finally, health economic analyses confirmed the cost-
effectiveness of the interventions in the DPP31,32.
Later studies
Published studies
The 2-year PRELLIM (Effect of LinagliptinþMetformin vs.
Metformin Alone in Patients with Prediabetes) trial evaluated
the benefits of adding the DPP4 inhibitor, linagliptin (or no
additional treatment) to metforminþ ILI in a population of
144 subjects with IGT47. The risk of developing diabetes was
higher in the metforminþ ILI group (hazard ratio [HR] 4.0
[1.2, 13.0]) and the likelihood of regressing to normoglycemia
was higher in the triple therapy group (HR 3.3 [1.6, 6.8]).
PREVENT-DM was a small (n¼ 92), pragmatic study in
obese Latina women with elevated, but non-diabetic, HbA1c
in an urban setting in the USA48. Subjects were randomized
to receive ILI (based on the DPP and promoted by commu-
nity health workers), metformin 850mg BID, or continued
usual care for one year. Mean weight loss was larger for ILI
(4.0 kg) than for metformin (1.1 kg). No data on diabetes
prevention per se were available from this small study, but
its importance lies in its demonstration of delivery of dia-
betes prevention interventions in a challenging setting.
Studies in progress
A 2-year study in China is randomizing subjects with
“impaired glucose regulation” (WHO 1999 diagnostic criteria)
to a lifestyle intervention with or without additional metfor-
min 850mg BID for at least 2 years. Its primary endpoint will
be the incidence of diabetes49. The Transdiab study will
evaluate the efficacy of metformin vs. placebo for reducing
the risk of post-renal transplant diabetes, a common compli-
cation of this procedure50,51. A cluster-randomized trial is in
progress in Mexico to evaluate the cost-effectiveness of inter-
vention with ILI with or without metformin for 3060 obese
subjects with IGT52. The primary endpoint will be the inci-
dence of type 2 diabetes.
Other trials, described but yet to report, continue the shift
away from the primary measurement of incident diabetes to
other endpoints, including clinical outcomes, as summar-
ized below.
Clinical cardiovascular outcomes: GLINT (Glucose
Lowering In Non-diabetic hyperglycemia Trial) was conceived
as a clinical outcomes study of metformin XR (up to
1500mg/day) vs. placebo in people with non-diabetic hyper-
glycemia and risk factors for cardiovascular disease53. It is
currently unclear if and when the main part of this study will
proceed, due to serious problems relating to the recruitment
of subjects, a high level of treatment discontinuation, and
funding issues53. The VA-IMPACT (Investigation of
Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular
OuTcomes) study is currently recruiting a population of
about 8000 people with any form of non-diabetic hypergly-
cemia at elevated cardiovascular risk for randomization to
metformin XR or placebo (NCT02915198). The primary end-
point is a composite of cardiovascular events.
Additional trials being planned or in progress in popula-
tions with non-diabetic hyperglycemia will not evaluate the
incidence of diabetes as their primary endpoint:
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Personalized vs. general calorie-restricted die-
t1metformin: The Personalized Medicine in Pre-diabetes-
Towards Preventing Diabetes in Individuals at Risk (PREDICT)
study will randomize antihyperglycemic agent-naïve subjects
with non-diabetic hyperglycemia to 6months of either a per-
sonalized diet or a more general calorie-restricted diet, each
in addition to metformin XR 1500mg/day54. The primary
endpoint changes in HbA1c.
Heart failure (HF) outcomes: Strong pathogenetic links
have been revealed between diabetes and HF in recent
years55. The DAN-HEART study is including people with
comorbid HF and clinical diabetes or non-diabetic hypergly-
caemia56. The main outcome will be the incidence of cardio-
vascular events.
Frailty: Metformin has been shown to improve non-classical
cardiovascular risk factors that are also risk factors for develop-
ing frailty in later life57–59; conversely, frailty is a strong pre-
dictor of adverse outcomes in people with diabetes60. A 2-year
study is randomizing older (65 years), non-frail adults with
non-diabetic hyperglycemia to metformin or placebo to deter-
mine whether metformin can reduce the incidence of frailty6.
Observational data on diabetes prevention with
metformin in subjects with IGT and/or IFG
at baseline
The diabetes prevention program outcomes study
Principal analyses released to date
Long-term epidemiologic follow-up of the population of the
DPP has been conducted since the end of randomized treat-
ment, in the 88% of the DPP population who entered the
DPP Outcomes Study (DPPOS)61. All participants who were
receiving metformin in the randomized phase who were eli-
gible to continue receiving this treatment according to cur-
rent guidelines, and who did not require changes to
treatment according to their usual care physicians, were
offered continued treatment with metformin 850mg BID. All
participants additionally received group-based lifestyle inter-
vention, with subjects previously randomized to ILI receiving
additional lifestyle support. The DPPOS Investigators did not
provide recommendations on the use of metformin in the
prior ILI group. Treatment with a placebo was discontinued.
A significant level of diabetes prevention was still evident
in the metformin and lifestyle groups after 10 years of overall
follow-up (3 years of randomized treatment þ 7 years of epi-
demiological follow-up (Table 1)62,63. The overall incidence of
type 2 diabetes/100 person-years during the full ten years of
analysis was lowest in the prior ILI group (5.3 [4.8, 5.8]) than
in the prior metformin group (6.4 [5.9, 7.1]) or the prior pla-
cebo group (7.8 [7.2, 8.6]). However, the incidence rate dur-
ing the post-randomization (DPPOS) phase was higher for
prior ILI (5.9 [5.1, 6.8]) than for prior metformin (4.9 [4.2,
5.7]). This anomalous finding was attributed to a depletion of
genetically susceptible individuals in the prior metformin
group (some of these had already developed diabetes before
the DPPOS phase) and to a 1 kg average weight gain in the
ILI group (weight loss was maintained in the prior metfor-
min group)64.
Data on 15 years of total follow-up for the DPPOS have
been published65, but data for 22 years of total follow-up
have only been presented in a symposium at the 2020 con-
gress of the American Diabetes Association (Table 2)66: these
data remain unpublished and can be described in general
terms only at this time67,68. Diabetes prevention was still evi-
dent at average follow-up duration of 15 years and 22 years.
Compared with the prior placebo group, reductions in dia-
betes incidence for prior metformin were 18% at both time
points, and for prior ILI were 27 and 25%. Long-term dia-
betes prevention is therefore feasible with either interven-
tion, and their efficacy appears to have converged to some
extent over time. Figure 2 summarizes the effects of metfor-
min or ILI on diabetes risk at all time points in the DPP
or DPPOS.
There were no significant microvascular or macrovascular
benefits at 22 years associated with either intervention (as
seen elsewhere with ILI after 30 years of follow-up of the
DaQing diabetes prevention trial69). However, prevention of
diabetes per se was associated with a lower incidence of
major adverse cardiovascular endpoints (39%), eye disease
(57%), and kidney disease (37%). There was also a trend
towards fewer strokes in the prior metformin group, and a
trend for fewer cardiovascular events in those who started
metformin before age 45 years, although there were too few
events for a definitive analysis. The incidence of nephropathy
Table 2. Overview of findings relating to diabetes prevention from the DPP outcomes study (DPPOS).
Analysis Overview of main findings
10 years of follow-up62,63 Diabetes incidence rates/100,000 person-years were 4.9 (4.2, 5.7) for prior metformin, 5.9 (5.1, 6.8) for prior ILI, and 5.6 (4.8, 6.5)
for placebo
Overall RRR for incident diabetes were 18% (7, 28) for prior metformin and 34% (24, 42) for prior ILI
Weight loss on metformin was maintained during the DPPOS at 10 y (the prior ILI group gained an average of 1 kg)
Metformin and ILI were cost saving and increased QALYs vs. placebo; overall discounted incremental cost-effectiveness ratio
was USD 13,420 for ILI vs. metformin74
15 years of follow-up66–68 Significant diabetes prevention still present for the prior ILI group (RRR 27%) and the prior metformin group (RRR 18%)
No microvascular or macrovascular outcomes benefit for either active treatment – however, there were significant
cardiovascular and microvascular benefits for subjects who did not vs. did develop diabetes from the whole population
22 years of follow-up66–68 Significant diabetes prevention still present for the prior ILI group (RRR 25%) and the prior metformin group (RRR 18%)
No microvascular or macrovascular outcomes benefit for either active treatment – however, there were significant
cardiovascular (RRR 39% for MACE) and microvascular benefits (RRR 57% for eye disease and 37% for kidney disease)
for subjects who did not vs. did develop diabetes from the whole population
ILI: intensive lifestyle intervention; MACE: major adverse cardiovascular events; RRR: relative risk reduction.
Total follow-up is randomizedþ observational follow-up. References to “prior ILI” or “prior metformin” groups refer to subjects previously randomised to those
groups as no attempt was made to maintain randomised treatment during the DPPOS. Figures in parentheses (X, Y) are 95% confidence intervals.
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(albumin: creatinine ratio 30mg/kg) was higher at 20 years
follow-up in subjects aged 60 years in the prior metformin
group (0.3%), compared with the other prior treatment
groups (each 0.2%)67. The significance of this finding is
uncertain, as the magnitude of the difference was small, and
these data have only been presented in a symposium at the
time of writing, and peer-reviewed publication is awaited67.
Further analyses from the DPPOS
Additional important studies from the DPPOS population are
summarized below and in Table 3 72–77. Analysis at 15 years
total follow-up showed that metformin was more effective in
preventing diabetes in women with prior GDM (see below
for a more detailed description of effects in this population)
and subjects with higher severity of non-diabetic hypergly-
cemia at baseline70. Metformin reduced the risk of diabetes
by 17% (based on measurement of FPG) or by 39% (based
on measurement of HbA1c) in this study70.
Weight loss was an important determinant of diabetes
prevention in the DPP/DPPOS, as described above. Average
weight loss was greater for ILI than the other groups during
the randomized phase of the DPP, but maintenance of long-
term weight loss from years 6–15 was greatest for metfor-
min70. Greater weight loss in year 1 (all groups), older
ageþ continued metformin use (metformin group), and older
age and no diabetes or family history of diabetes (ILI group)
predicted long-term weight loss on active treatments.
Subjects with higher physical activity before the DPP ran-
domization had a greater risk of diabetes: this apparent para-
dox is explained by the observation that these subjects
demonstrated less increase in activity and less weight loss
than other subjects during the randomized phase of the trial.
Weight loss in the DPP/DPPOS correlated with adherence to
metformin71.
Elevated coronary artery calcium (CAC; measured using a CT
scanning technique) is a predictor of increased cardiovascular
risk that is used widely in clinical cardiovascular risk assess-
ment72. A study at 10 years of DPPOS follow-up (14 years on
average in all) found a reduced level of CAC scoring (based on
the severity of elevation, or on whether or not elevated CAC
was present) in men in the prior metformin group, but not in
other treatment groups, or women73. The effect in men was
independent of other clinical variables or receipt of statin treat-
ment and was hypothesized to represent a potential cardiopro-
tective effect of metformin in men with non-diabetic
hyperglycemia. Other evidence of a potential cardioprotective
effect of metformin in people with non-diabetic hyperglycemia
is available: for example, a prospective observational study
reported improved coronary artery endothelial function in peo-
ple with non-diabetic hyperglycemia (ADA criteria) who did vs.
did not receive metformin as part of their usual care74.
In another analysis, neither metformin nor ILI influenced
measures of cognition in the DPP/DPPOS75.
Other observational data
The Carmos study involved an observational comparison of
metformin (n¼ 95) or no additional treatment (n¼ 271) in a
population of overweight or obese subjects free of diabetes
or cardiovascular disease at baseline76. Additional metformin
treatment reduced the incidence of diabetes in the overall
population (risk difference 7% [13, 1], p¼ .012), with a
larger effect in subjects with “prediabetes” (undefined; risk
difference 19% [33, 4], p¼ .010). Treatment with metfor-
min also reduced the risk of developing metabolic syndrome
(risk difference 13% [25, 1], p¼ .040), mainly due to
increased HDL-C and reduced plasma glucose.
An uncontrolled, 12-week observational study conducted
in Poland and Hungary showed that 3months of treatment
Figure 2. Summary of relative risk reductions for type 2 diabetes in the Diabetes Prevention Program (DPP) and its epidemiological follow-up study, the Diabetes
Prevention Program Outcomes Study (DPPOS). aRelative to placebo (DPP) or subjects formerly randomised to placebo (DPPOS). bRandomized phase. cEpidemiologic
follow-up. Bars are 95%CI. Points and bars have been displaced laterally where they overlap to improve clarity (all pairs of measurements were from the same time
points). Compiled from data presented in references14,62,65–68.
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with metformin XR, administered according to usual care
conditions under the care of subjects’ physicians to 686 sub-
jects with non-diabetic hyperglycemia based on measure-
ments of FPG or HbA1c36. There was no formal diagnosis of
diabetes included within the study, but 43% of subjects had
their FPG reduced to below the 5.7mmol/L cut-off used
commonly for the diagnosis of IFG (Box 1). Data from 123
subjects with IFG, IGT, or both showed that intervention with
ILI, ILIþmetformin or ILIþDPP4 inhibitor reduced weight,
fasting and post-load glycemia and triglycerides77.
Diabetes prevention with metformin in other states
characterized by insulin resistance
Gestational diabetes
A pregnancy complicated by GDM increases the 10-year risk of
future type 2 diabetes substantially78. For example, the risk of
developing type 2 diabetes was 48% higher over 10 years for
women with vs. without prior GDM in the placebo group of the
DPPOS79. Women with a history of GDM in the prior metformin
and prior ILI groups in the DPPOS were at lower risk of subse-
quent development of T2D (relative risk reduction [RRR] 40
and 35%, respectively, vs. women in the prior placebo
group79. ILI was also effective in preventing diabetes in the sub-
group without prior GDM (RRR 30%), although metformin was
not. These long-term effects were comparable to those seen in
the earlier, randomized phase of the trial80. A feasibility trial is
underway to support a future placebo-controlled trial that will
evaluate the effects of metformin vs. placebo on health out-
comes (including incident diabetes) in women with GDM81.
Polycystic ovary syndrome
PCOS is an insulin-resistant state that is the most common
cause of anovulatory infertility82. Treatment with metformin
has been shown to ameliorate the dysglycemia, overweight,
and hyperandrogenism that characterizes PCOS, and guide-
lines recommend a second-line role for metformin in improv-
ing fertility in this population83,84. Information is lacking on
whether metformin can prevent the onset of T2D in women
with PCOS85. Several observational studies suggested a
significant effect of metformin in reducing the risk of future
GDM in women with PCOS; meta-analyses of randomized tri-
als do not support such an effect, however86,87.
Who should receive metformin for
diabetes prevention?
Current guidelines
Internationally-influential guidance from Europe (jointly from
the European Society of Cardiology [ESC] and the European
Association of the Study of Diabetes [EASD])6, the ADA9, and
the UK National Institute for Health and Care Excellence
(NICE)88 stress lifestyle intervention as the initial intervention
to reduce the excess risk of incident diabetes. This is consist-
ent with the well-known association between increased risk
of T2D and overweight or obesity and physical inactivity, as
described above. All people at risk of (or with) type 2 dia-
betes who can adopt an intensive lifestyle intervention
should do so throughout life.
The ADA and NICE guidelines support the therapeutic use
of metformin for diabetes prevention in defined circumstan-
ces, while the ESC/EASD guideline provides no recommenda-
tion on the pharmacologic management of non-diabetic
hyperglycemia (Table 4). Recommendations on the use of
metformin generally reflect the findings of the DPP, favoring
the use of metformin alongside lifestyle change for younger
subjects with higher levels of BMI. Long-term safety monitor-
ing is highlighted including the importance of periodic
checks of vitamin B12 and renal function (to ensure that
patients have not developed a renal contraindication to met-
formin). The NICE guidance notes additionally that the
evidence base for diabetes prevention has been gained
with the immediate-release formulation, but that prolonge-
d/extended-release formulation of metformin is now indi-
cated for the prevention or delay of diabetes and may be
useful for people who cannot tolerate immediate-
release metformin.
Numerous national and regional guidelines on the use of
metformin forþdiabetes prevention have been developed
and are reviewed elsewhere8. Most contained
Table 3. Further published analyses from the DPP outcomes study (DPPOS).




Metformin was more effective in women with vs. without prior GDM (rate difference [RD] 6.6 diabetes cases/100-PY, p¼ .01) and in
subjects with higher baseline FPG (RD 3.5 cases/100 PY for FPG 110mg/dL (6.1mmol/L) or HbA1c (RD 3.9 cases/100 PY for
baseline HbA1c 6.0–6.4%, p¼ .0001)
Long-term weight
loss (15 years)111
At 1 year, 29% (metformin) 63% (ILI) and 13% (placebo) had lost 5% initial body weight, but maintained weight loss for years 6–15
was greater for metformin (6.2% [5.2, 7.2]) vs. ILI (3.7% [3.1, 4.4]) or placebo (2.8% [1.3, 4.4]) in the placebo; weight loss in year 1
Coronary calcium
(14 years)73
Less coronary artery calcium (CAC; measured as severity or presence vs. absence on imaging) was present in men (age-adjusted mean
CAC severity: 39.5 vs. 66.9 Agatston units, p¼ .04; CAC presence: 75 vs. 84%, p¼ .02); no effect in women was seen and the effect in
men was independent of diabetes, demographic, anthropometric, or metabolic factors, or receipt of statin treatment
Frailty (14 years)112 Being in the prior ILI group was associated at year 10 of follow-up with a reduced risk of frailty compared with metformin (OR 0.63
[0.42, 0.94], p¼ .022) or prior placebo (OR 0.62 [0.42, 0.93], p¼ .022; the risk of frailty in the prior metformin did not differ from that
for prior placebo (OR 0.99 [0.69. 1.42], p¼ .976)
Cognition (14 years)75 Exposure to neither ILI nor to metformin predicted changes in cognition; higher HbA1c predicted impaired cognition, but presence vs.
absence of type 2 diabetes did not
Malignancy113 Randomization to neither metformin nor ILI affected the incidence of cancer significantly during follow-up in the DPPOS.
FPG: fasting plasma glucose; ILI: intensive lifestyle intervention; PY: person-years; RRR: relative risk reduction.
Total follow-up is randomizedþ observational follow-up. References to “prior ILI” or “prior metformin” groups refer to subjects previously randomised to those
groups as no attempt was made to maintain randomised treatment during the DPPOS. Figures in parentheses (X, Y) are 95% confidence intervals.
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recommendations on the use of metformin consistent with
those of the ADA and NICE, as summarized in Table 4.
Is metformin underused in populations with
non-diabetic hyperglycemia?
Studies to date suggest that only a small proportion of peo-
ple with non-diabetic hyperglycemia receive metformin for
this condition. For example, a study from the USA reported
that the prevalence of self-reported “prediabetes” increased
from 5.1% in 2005–2006 to 7.4% in 2013–2014, with a corre-
sponding increase in the use of metformin from 2.4 to 8.3%
over this period89. Also in the USA, only 0.7% of adults with
“prediabetes” were reported to receive metformin between
2005 and 201290. Only 1.9% of people with prediabetes and
BMI 35 kg/m2, a subgroup with strong support for metfor-
min use in guidelines (see above) were reported to have
received metformin in this study. Similarly, a third US study
found that only 8.1% of a population of younger people
(age <60 years) with non-diabetic hyperglycemia (HbA1c
5.7–6.4%) at high risk of diabetes through prior GDM and
BMI 35 kg/m2 received metformin91.
The cluster-randomized Prediabetes Informed Decisions
and Education (PRIDE) study explored the outcomes of shared
decision-making on treatment options among a population of
515 subjects who were about to undertake a diabetes preven-
tion intervention92. Pharmacists discussed the contents of evi-
dence-based clinical decision aids for the principal approaches
to diabetes prevention. Most subjects opted for ILI (55%), com-
pared with metformin (9%), or both (15%), while 26% declined
both. Women and older patients were more likely to choose ILI
while increasing BMI predicted higher take-up of both ILI and
metformin. Metformin appears to be underused among the
population of subjects eligible for it.
Other issues relating to the therapeutic use of
metformin for diabetes prevention
Adherence
The majority of the insulin-secreting capacity from pancreatic
b-cells has already been lost by the time prediabetic
dysglycemia becomes apparent93, and metformin does not
alter the continuing rate of loss of b-cells as clinical diabetes
subsequently becomes established94. Accordingly, the
pharmacologic treatment of prediabetes will be for life and
its success will depend on adequate adherence of people
with prediabetes to the treatment regimen. Experience from
populations with type 2 diabetes shows that periods of non-
use of metformin are common during long-term treatment95.
The DPPOS reported recently that about one-quarter of sub-
jects eligible for metformin did not take it, and that 478/868
subjects reported problems with adherence to metformin
over an 11-year period96. Higher depression scores, Black
ethnicity, and lower initial adherence in the randomized
phase of the DPP were among the factors associated with
poorer adherence. Strategies to optimize adherence to met-
formin will be needed, especially given the asymptomatic
nature of non-diabetic hyperglycaemia97. Some trials in pro-
gress in populations with non-diabetic hyperglycemia,
described above, are using the XR formulation of metformin,
which may support better adherence to therapy than the
immediate-release formulation, based on clinical experience
in people with type 2 diabetes98.
Tolerability and safety
The main side-effect of metformin seen in people with type
2 diabetes, i.e. gastrointestinal upsets, such as diarrhea,
abdominal pain, and nausea/vomiting, were apparent in the
DPP/DPPOS71 and other randomized trials listed in Table 1;
these can be minimized by careful initial dose titration, a
(usually temporary) dose reduction where necessary, or use
of an extended-release formulation99,100. No significant safety
issues were observed in the randomized phase of the DPP,
and during 7–8 years of follow-up thereafter in the DPPOS71.
Twenty-two cases of hypoglycemia were reported among
the 531 participants in the IDDP33, a side-effect not usually
associated appreciably with metformin in populations with
type 2 diabetes. Careful titration from a low starting dose
may be useful in non-diabetic subjects, to limit the incidence
of side-effects99.
Table 4. Overview of recommendations relating to the use of metformin for the prevention or delay of type 2 diabetes from selected guidelines with inter-
national influence.
Sponsor (year) Summary of recommendation relating to metformin
ADA9 Consider adding metformin to lifestyle intervention especially for those with BMI 35 kg/m2, those aged <60 years, and women
with prior GDM
Monitor vitamin B12 periodically, especially where anemia or peripheral neuropathy is present
ESC/EASD6 This guideline includes recommendations on lifestyle changes to reduce the risk of new-onset diabetes and cardiovascular risk in
subjects with “prediabetes” or diabetes, but does not include any recommendations on interventions on pharmacological
intervention in people with non-diabetic hyperglycemia new-onset type 2 diabetes in people with non-diabetic hyperglycaemia
NICE87 Use clinical judgement on whether to add metformin to (continued support for) lifestyle intervention for people whose HbA1c is
rising despite an attempt at a lifestyle intervention, or for people who are unable to undertake one
Consider metformin in these situations especially if BMI is 35 kg/m2
Discuss potential risks and benefits carefully, including the potentially lifelong nature of treatment
Try metformin for 6–12months and discontinue if there is no improvement in glycaemia
Monitor renal function initially and periodically (at least twice/per year)
ADA: American Diabetes Association; BMI: body mass index; EASD: European Association of the Study of Diabetes; ESC: European Society of Cardiology; NICE:
National Institute for Health and Care Excellence (UK).
All guidelines stress the importance of lifestyle change as the first-line approach to diabetes prevention (see text), and this should be continued during treat-
ment with metformin where possible. Guidance has been paraphrased for conciseness here and readers should always consult the full guidance.
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Lactic acidosis is an extremely rare complication of the
treatment of type 2 diabetes with metformin, and the con-
traindications of this agent are designed to avoid its use dur-
ing the settings of severe renal impairment and
hypoperfusion/hypoxia that might predispose to metformin-
associated lactic acidosis56. The prevalence of these condi-
tions in subjects with non-diabetic hyperglycemia has not
been investigated to our knowledge, but it is likely to be
lower than in people with type 2 diabetes of long duration
who may be receiving metformin and who may be at risk of
developing potential contraindications to metformin, such as
severe chronic kidney disease or severe acute HF, etc.
Reduced levels of vitamin B12 is a well-known side-effect
of metformin treatment during treatment for type 2 dia-
betes101 and has been observed in the DPPOS102. The
authors recommended period screening and B12 supplemen-
tation, where required, during treatment with metformin.
Metformin has been in continuous clinical use for more
than six decades in the management of type 2 diabetes, and
its tolerability and safety profiles are well-understood103.
There is no evidence to suggest that the long-term safety of
metformin differs according to the severity of dysglycemia. It
is reasonable to assume that the well-established safety and
tolerability profiles of metformin observed in people with
diabetes will likely apply to people taking metformin to pre-
vent or delay type 2 diabetes, at least until further evidence
accumulates relating to the therapeutic profile of metformin
specifically in people with non-diabetic hyperglycemia.
Health economics
Numerous reports, reviewed elsewhere8, have concluded that
metformin and ILI based on the DPP are effective and cost-
effective approaches to reducing the risk of diabetes in peo-
ple with non-diabetic hyperglycemia. A systematic review
published in 2017 calculated that median incremental cost-
effectiveness ratios [ICER] were GBP 7490/quality-adjusted
life-year (QALY) for ILI and GBP 8428/QALY for metformin;
however, variations between studies in their populations,
definitions of non-diabetic hyperglycemia, the nature of the
interventions and assumptions used in constructing health
economic models contribute to considerable variations in
the results of individual studies104.
Some studies adapted the DPP-based ILI for delivery
within a community setting. The PREVENT-DM study,
described above, is an interesting example of this approach,
in its use of community health workers (“promotoras”) to
support people with the study interventions in its urban
environment48, as maintaining adherence to a lifestyle
change is central to optimizing the benefits from it105. The
use of “Diabetes Prevention Mentors” did not enhance the
effectiveness of a community-based diabetes prevention ini-
tiative in the UK, however106. The nature of a lifestyle inter-
vention is critical to its effectiveness and cost-effectiveness,
however. A recent report from the UK found that low-impact
lifestyle intervention was highly cost-effective compared with
no intervention, at an incremental cost-effectiveness ratio
[ICER] of GBP 44/quality-adjusted life-year (QALY), but would
deliver only a 7% reduction in diabetes incidence over 10
years107. Metformin was cost-effective at an ICER of GBP
372–5224/QALY, and ILI at an ICER of GBP 2775–7376/QALY,
depending on whether diabetes was diagnosed using plasma
glucose, OGTT glucose, or HbA1c; metformin was cost-effect-
ive compared with either lifestyle intervention when HbA1c
was used for diagnosing diabetes. The cost itself is a factor,
irrespective of cost-effectiveness. For example, a recent
report from Singapore concluded that ICERs of USD 36,663
for ILI (based on the DPP and adapted to local conditions) or
metformin (USD 6367) was cost-effective from a societal per-
spective108. However, the authors concluded that the ILI
would need to be delivered at a lower cost to be feasible for
use as a strategy for diabetes prevention in Singapore.
Summary and conclusions
The potential of metformin to delay or prevent new-onset
type 2 diabetes in people with IGT is proven beyond doubt
by multiple randomized, controlled trials. Intensive lifestyle
intervention was more effective than metformin in prevent-
ing diabetes in the DPP and elsewhere, although the efficacy
of these interventions was similar in the lowest age category
and highest BMI category in the main analysis of the
randomized phase of the DPP14. Accordingly, lifelong support
for an improved lifestyle should be offered to all at risk of
diabetes, but guidelines support a role for metformin in peo-
ple for whom lifestyle intervention is ineffective or impracti-
cal, especially where obesity is severe8. Physicians and
people with non-diabetic hyperglycemia need to make indi-
vidualized and shared decisions on whether treatment with
metformin is appropriate for that individual.
Importantly, clinically and statistically significant levels of
diabetes prevention were present two decades after the ces-
sation of randomized treatment in the DPP/DPPOS, for peo-
ple initially randomized to either ILI or metformin, relative to
those initially randomized to placebo. The RRR for diabetes
in the prior metformin group remained the same at 10, 15,
and 22 years of follow-up at 18% (Table 2, Figure 2). These
findings were especially notable as there was no effort to
maintain DPP-randomized treatments during the DPPOS
(although eligible patients in the metformin group were
offered continued treatment). These data attest to the feasi-
bility of long-term diabetes prevention with metformin.
Important research questions remain. We have yet to see
improved clinical cardiovascular or microvascular outcomes
in members of either the prior ILI or prior metformin groups
from the DPPOS, or elsewhere. The observation from 22
years of follow-up that prevention/delay of diabetes per se in
these groups combined was associated with significant out-
comes benefits was encouraging. Further follow-up and
more clinical events will be required to establish whether the
cardiovascular benefits observed in people with type 2 dia-
betes randomized to metformin in the UK Prospective
Diabetes study will be observed in the DPPOS population
previously randomized to metformin94.
Further data to support a precision medicine approach for
targeting the most appropriate subjects to receive metformin
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will also be useful. We know that weight loss is a crucial part
of any intervention for diabetes prevention, and this has
been observed with metformin in the DPP and elsewhere, as
described above The observation in the DPP that women
with GDM benefitted especially from treatment with metfor-
min (and that women without prior GDM did not)78 requires
further study. The potential for metformin to prevent/delay
diabetes in other populations, such as those with PCOS85, or
perhaps antidepressant-induced weight gain and dysglycae-
mia109, may be of interest in the future. Further study of
populations with isolated IFG would be of interest, as metfor-
min has not yet been clearly shown to reduce the incidence
of diabetes in this population13, but metformin was more
effective in subjects with IGT with higher vs. lower FPG in
the DPP14,110. Finally, diabetes prevention studies have used
varying dosing schedules for metformin, and the optimal
dose of metformin for this purpose has yet to be defined.
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